RxDoctor Payments Data

Lori Saunders

Family · Murrieta, CANPI 1215991088

Payments from drug & device makers

$5,413in general payments, 2019–2025

Across 280 payments — averaging $19.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Johnson & Johnson$660
  • Takeda Pharmaceuticals U.S.A., Inc.$549
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$450
  • QOL Medical, LLC$410
  • Regeneron Healthcare Solutions, Inc.$201
  • plus $974 from 13 others

What the payments were for

  • Food & beverage$5,32398%
  • Education$902%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,413 in reported general payments places this provider in the 95th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$33,708
Medicare patients
268
Services billed
330

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase21$78,401
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates390$22,300
SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag110$13,692
Mesalamine24$5,892
Mesalamine DrMesalamine13$4,669
Cholestyramine LightCholestyramine22$1,991
SutabSod Sulf/Pot Chloride/Mag Sulf11$1,813
Sucralfate29$1,755
Pantoprazole Sodium95$1,061
Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl58$928
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg38$771
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl35$505
Ondansetron OdtOndansetron30$435
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine12$371
Omeprazole43$294

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon$2,169$78,40121 claims
Braintree Laboratories, Inc.Suflave, Sutab$56$15,505121 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,634 family providers in California.

Other family in Murrieta

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →